theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Psychiatry

Ketamine   

Questions discussed in this category


How do you determine the treatment course of esketamine or IV ketamine when used for treatment-resistant major depressive disorder?
1 Answer available
20838


Papers discussed in this category


Biological psychiatry, 2010-01-15
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Molecular psychiatry, 2018-10-03
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).

Journal of affective disorders, 2020 Jul 21
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.

The Journal of clinical psychiatry, 2023 Feb 01
Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.

CNS drugs, 2023 Aug 09
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023 May 12
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.

Related Topics in Psychiatry

  • Breast Cancer
  • Head and Neck Cancers
  • Radiation Oncology
  • Neuro-Oncology
  • Pediatric Hematology/Oncology
  • Ethics
  • Medical Oncology
  • Biologic Therapy/Immunobiology
  • Epilepsy
  • General Internal Medicine

Copyright © 2025 theMednet
All Rights Reserved.